We’ll help you find the highest quality medicine that you need.
is indicated for the treatment of HIV-1 infection in patients 12 years of age and older as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL. Odefsey can also replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey.
Manufactured by: Gilead Sciences, Inc
Active Ingredient(s): Emtricitabine; Rilpivirine Hydrochloride; Tenofoviral Afenamide Fumarate
Dosage Form: Film Tablet, oral
Strength: Each tablet contains 200 mg of Emtricitabine (FTC), 25 mg of RPV (equivalent to 27.5 of Rilpivirine Hydrochloride) and 25 mg of Tenofovir (equivalent to 28 mg of Tenofovir Alafenamide Fumarate)
FDA approved: March 1, 2016
More information about Odefsey:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208351s000lbl.pdf
https://www.gilead.com/~/media/files/pdfs/medicines/hiv/odefsey/odefsey_pi.pdf?la=en
is indicated for the treatment of idiopathic pulmonary fibrosis.
Manufactured by: Boehringer Ingelheim
Active Ingredient(s): Nintedanib Esylate Ethanesulfonate,
Dosage Form: Capsule, oral
Strength: 100 mg, 150 mg
FDA approved: October 15, 2014
More information about Ofey:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ofev/ofev.pdf
is indicated for the treatment of adult patients with active psoriatic arthritis and in patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Manufactured by: Celgene Corp
Active Ingredient(s): Apremilast
Dosage Form: Tablet, oral
Strength: 10 mg, 20 mg and 30 mg
FDA approved: March 21, 2014
More information about Otezla:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205437s000lbl.pdf